一种联合使用选择性5-羟色胺再摄取抑制剂（SSRIs）和甘丙肽N端片段（1-15）治疗抑郁症的新增强策略。
A New Augmentation Strategy against Depression Combining SSRIs and the N-terminal Fragment of Galanin (1-15).
作者信息
Flores-Burgess Antonio, Millon Carmelo, Cantero-Garcia Noelia, Pineda-Gomez Juan Pedro, Flores-Gomez Marta, Diaz-Cabiale Zaida
机构信息
Departamento de Fisiología, Facultad de Medicina, Universidad de Málaga, Campus de Teatinos s/n. 29080 Málaga, Spain.
出版信息
Curr Neuropharmacol. 2025;23(3):295-309. doi: 10.2174/1570159X23666241003125019.
Depression is one of the most disabling mental disorders, with the second highest social burden; its prevalence has grown by more than 27% in recent years, affecting 246 million in 2021. Despite the wide range of antidepressants available, more than 50% of patients show treatment-resistant depression. In this review, we summarized the progress in developing a new augmentation strategy based on combining the N-terminal fragment of Galanin (1-15) and SSRI-type antidepressants in animal models.
抑郁症是最具致残性的精神障碍之一，社会负担位居第二；近年来其患病率增长超过27%，2021年有2.46亿人受其影响。尽管有多种抗抑郁药可供使用，但超过50%的患者表现出难治性抑郁症。在本综述中，我们总结了在动物模型中基于联合甘丙肽N端片段（1-15）和SSRI类抗抑郁药开发新的增效策略的进展。
Zotero 插件